192 results
Page 2 of 10
8-K
EX-99.1
sbni02d
13 Nov 23
Regulation FD Disclosure
8:05am
8-K
EX-99.1
cv3xfl7 rk8ir13uu2
13 Nov 23
Moleculin Reports Third Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
eccdzwd2
6 Nov 23
Regulation FD Disclosure
8:35am
8-K
EX-99.1
u9koedgpnv72
2 Oct 23
Regulation FD Disclosure
8:40am
8-K
EX-99.1
bggxve7 on09p
21 Sep 23
Regulation FD Disclosure
8:50am
8-K
EX-99.1
7chl0 4qkpda5
18 Sep 23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
8:40am
8-K
EX-99.1
02bd5ipx4ob8hrbm
14 Sep 23
Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
8:35am
8-K
EX-99.1
5jckkvfu5c5igw ip
11 Aug 23
Moleculin Reports Second Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
aql9fc8z54v5v
10 Aug 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:05pm
8-K
EX-99.1
ag7p0ivwld86l5fqp
7 Aug 23
Regulation FD Disclosure
8:40am
8-K
EX-99.1
luxfb4edxdlhgd6huanj
13 Jul 23
Regulation FD Disclosure
12:00am
8-K
EX-99.1
mtuis 2rz7rkor0opa5
11 May 23
Moleculin Reports First Quarter 2023 Financial Results
7:05am
8-K
EX-99.1
0hy5mdqhrswb
10 May 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:07pm
8-K
EX-99.1
gr6v rmiwxtx18mad
2 May 23
Preliminary results demonstrate a durable complete response at starting dose level in elderly subject
8:35am
8-K
EX-99.1
lw1yjqu
18 Apr 23
Sponsored research data presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023
1:35pm
8-K
EX-99.1
mkfv3p7
21 Dec 22
Regulation FD Disclosure
8:25am
8-K
EX-99.1
yivbnsk73
15 Dec 22
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock
8:37am
8-K
EX-99.1
9ci5rtmb517 yvoy0tb
7 Dec 22
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
8:45am